Hyperuricemia remains the leading risk factor, but the runners-up may surprise you.
Here: the latest evidence on the effects of febuxostat, allopurinol, and statins on CV mortality in patients with gout.
Despite its antioxidant properties, uric acid may not be as neuroprotective as previously thought.
Recent findings call into question the safety of long-term febuxostat therapy in patients with cardiovascular disease.
Should urate-lowering therapy be continued during an acute gout attack? Which antihypertensive has mild uricosuric effects? Test yourself with these questions and more.
Among the highlights of 3 recent studies: insights into hormonal risk factors for rheumatoid arthritis.
Highlights of 3 recent studies that can affect your practice: a novel procedure for knee pain, cardiovascular risk in RA, and febuxostat in early gout.
A green light for dosing to achieve the target urate level.
To paraphrase Winston Churchill, rarely have so few been called upon by so many.
Complaints about loss of self, loss of role identity, and lower quality of life dominate within this patient population.